Diabetic retinopathy and diabetic macular edema remain the leading cause of vision loss among adults. Yet, we continue to see high rates of vision loss. See how our experts, Dr. Vivian Fonseca and Dr. Rishi Singh, are identifying which populations are the most vulnerable and the barriers faces. Then learn about the exciting new strategies that are emerging to improving screening and vision outcomes.
Frontiers in Diabetic Macular Edema: New Ways to Address Barriers and Health Disparities for Better Vision Outcomes
Frontiers in Diabetic Macular Edema: New Ways to Address Barriers and Health Disparities for Better Vision Outcomes
Diabetic macular edema and diabetic retinopathy are the 2 most common visual complications of diabetes.1 Furthermore, diabetic retinopathy is the leading cause of vision loss among working-age adults.1 We know that screening works and effective treatments are available, so why do we continue to see high rates of vision loss?
Racial and Social Influences on Diabetic Eye Disease
First, we know the prevalence of diabetes is higher among minority populations and those with lower socioeconomic status.2,3 Data from the National Health and Nutritional Evaluation Survey 2005-2008 also show that diabetic retinopathy is 190% higher in non-Hispanic Blacks compared with Whites.4 Social determinants of health and glycemic control as well as barriers to care can influence the progression of diabetic retinopathy and diabetic macular edema (Figure 1).5,6
A recent study highlights how socioeconomic barriers specifically affect the vision of patients with diabetes. Queries of the American Academy of Ophthalmology’s Intelligent Research in Sight (IRIS) database showed that patients with diabetic macular edema who are Black or Hispanic presented with worse baseline visual acuity compared with their White and non-Hispanic counterparts (Figure 2).7
In addition, insurance stratification was associated with differences in baseline visual acuity. Patients with private insurance were more likely to have good baseline visual acuity (£20/40) compared with patients who had Medicare or Medicaid (Figure 3).
The difference between 20/40 vision and 20/50 vision is the ability to drive versus reliance on others to attend healthcare appointments, which can further compound the social determinants of health. Unfortunately, data show that Hispanic and Black patients are at a high risk of non-improvement despite treatment with anti-vascular endothelial growth factor (VEGF) drugs (Figure 4).
Screening Advances to Improve Early Detection
Screening is essential to detect early problems with vision because treatments are most effective when started early; however, there are not enough eye doctors to screen every patient. Non-mydriatic fundus imaging, telemedicine, and reading centers are currently used to improve screening in primary care and endocrinology clinics. New technologies include artificial intelligence (AI) to recognize whether patients require further care by an eye doctor.8-10 AI could potentially be coupled with smartphone-based imaging to give patients an indication of when they need to be seen by an eye health professional.11 These advances in screening are important because the vast majority of patients do not have visual symptoms until very late in the disease state. In essence, patients are unknowingly sitting on a ticking time bomb.
In 2020, the first AI algorithm in all of medicine was approved for detecting diabetic retinopathy.12 The device is used with a traditional non-mydriatic camera. Images are captured, sent, and automatically read over a short period of time. The system then provides referrals with 87% sensitivity and 90% specificity for more than mild diabetic retinopathy.13
In addition to AI, the use of ultrawide field imaging is likely to become more common in practice. Traditional imaging methods take a 30° or 40° field of view, which can be equated to looking only at Iowa on a map of the United States while trying to figure out what is happening in California. Ultrawide field imaging provides a picture of the entire United States in one photograph which allows for more reliable detection of diabetic retinopathy.
Importance of Interdisciplinary Care and Advocacy Within Underserved Communities
Interdisciplinary teams consisting of patients, caregivers, and community leaders are also important to overcoming health disparities. Community leaders can help educate others on the social determinants of health and dispel rumors. Minority communities should know that diabetes and diabetic eye disease are conditions that can be screened for and that are treatable. The use of anti-VEGF agents can reduce diabetic eye disease progression significantly.
Improving Anti-VEGF Durability to Reduce Treatment Burden
One of the drawbacks of current anti-VEGF therapies is the need for frequent injections in patients with diabetic eye disease. The frequency of these injections is a significant burden for patients as well as providers. New treatments with greater durability are currently being studied. One strategy is in the form of an implant which can release an anti-VEGF agent over a long period of time.14 Another drug is taking a new approach by concurrently inhibiting angiopoietin-2 and VEGF to improve vessel integrity and increase treatment durability.15 Finally, brolucizumab is a high-dose drug with a higher potency than current anti-VEGF agents that is also being tested to see if durability is increased over time.16
Diabetes and diabetic eye disease are commonplace. As such, it is important for patients with diabetes to understand that yearly vision screening is very important because symptoms are not present early in the disease state. Initiating treatment before symptoms are present can prevent poor vision outcomes over the long term. Patients with diabetes should also understand that a vast majority of people will not lose vision as long as they see an ophthalmologist or retina specialist for routine eye examinations and undergo treatment when necessary. All of these are good reasons to be hopeful for the future.
For colleagues who are in endocrinology and primary care, it is important to keep abreast of new developments for the treatment of diabetic eye disease. As emerging treatments become available, they will be incorporated within the overall care plan for patients.
Ensure that patients, particularly those in socioeconomically challenged patient populations, are screened by using new technologies as they become available. Appropriate action needs to be taken early to achieve the level of outcomes that are seen in clinical trials. Ophthalmologists can do a lot for patients, but outcomes can only be improved if patients are educated about the importance of screening and treatment.
- Centers for Disease Control and Prevention. Common eye disorders and diseases. Reviewed June 3, 2020. Accessed May 6, 2021. https://www.cdc.gov/visionhealth/basics/ced/index.html
- Centers for Disease Control and Prevention. Prevalence of both diagnosed and undiagnosed diabetes. Reviewed June 24, 2020. Accessed May 6, 2021. https://www.cdc.gov/diabetes/data/statistics-report/diagnosed-undiagnosed-diabetes.html
- Agardh E, Allebeck P, Hallqvist J, Moradi T, Sidorchuk A. Type 2 diabetes incidence and socio-economic position: a systematic review and meta-analysis. Int J Epidemiol. 2011;40(3):804-818.
- Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010;304(6):649-656.
- McBrien KA, Naugler C, Ivers N, et al. Barriers to care in patients with diabetes and poor glycemic control-A cross-sectional survey. PLoS One. 2017;12(5):e0176135.
- Hill-Briggs F, Adler NE, Berkowitz SA, et al. Social determinants of health and diabetes: a scientific review. Diabetes Care. 2020;44(1):258-279.
- Malhotra NA, Greenlee TE, Iyer AI, Conti TF, Chen AX, Singh RP. Racial, ethnic, and insurance-based disparities upon initiation of anti-vascular endothelial growth factor therapy for diabetic macular edema in the US. Ophthalmology. Published online March 11, 2021. doi:10.1016/j.ophtha.2021.03.010
- Wong TY, Bressler NM. Artificial intelligence with deep learning technology looks into diabetic retinopathy screening. JAMA. 2016;316(22):2366-2367.
- Ting DSW, Cheung CY, Lim G, et al. Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetes. JAMA. 2017;318(22):2211-2223.
- Gulshan V, Rajan RP, Widner K, et al. Performance of a deep-learning algorithm vs manual grading for detecting diabetic retinopathy in India. JAMA Ophthalmol. 2019;137(9):987-993.
- Natarajan S, Jain A, Krishnan R, Rogye A, Sivaprasad S. Diagnostic accuracy of community-based diabetic retinopathy screening with an offline artificial intelligence system on a smartphone. JAMA Ophthalmol. 2019;137(10):1182-1188.
- Leonard C. Ophthalmologists in the machine: the AI era. Review of Ophthalmology. November 5, 2020. Accessed May 6, 2021. https://www.reviewofophthalmology.com/article/ophthalmologists-in-the-machine-the-ai-era.
- Abràmoff MD, Lavin PT, Birch M, Shah N, Folk JC. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. NPJ Digit Med. 2018;1:39.
- Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial. Ophthalmology. 2019;126(8):1141-1154.
- Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019;126(8):1155-1170.
- Tadayoni R, Sararols L, Weissgerber G, Verma R, Clemens A, Holz FG. Brolucizumab: a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration. Ophthalmologica. 2021;244(2):93-101.
In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Vivian Fonseca, MD
Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, LA
Contracted Research Support: Fractyl
Honoraria for Consulting and Lectures: Abbott, Asahi, AstraZeneca, Bayer, Intarcia,
Novo Nordisk, Sanofi- Aventis, Takeda
Stock Options: BRAVO4Health, Mellitus Health
Rishi P. Singh, MD
Staff Physician, Cole Eye Institute
Cleveland Clinic Foundation
Professor of Ophthalmology
Lerner College of Medicine, Case Western Reserve University
Consulting Fees: Alcon, Bausch and Lomb, Genentech, Gyroscope, Novartis, Regeneron
Contracted Research: Aerie, Apellis, Graybug
- Stephen Chavez has nothing to disclose.
- Ann Early has nothing to disclose.
- Anna Trentini has nothing to disclose.
- Stephanie Wenick, MPhil, has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Explain why the risk of DME-related blindness is heightened in vulnerable populations impacted by gaps in health equity
- Describe the barriers that may prevent the optimization of treatment for DME in vulnerable populations and strategies to overcome them
This activity is designed to meet the educational needs of ophthalmic surgeons, ophthalmologists, diabetologists, endocrinologists, primary care physicians, optometrists, and retina specialists.
Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Global Learning Collaborative designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Charles Wykoff, MD, PhDPeer